FU
Fulcrum Therapeutics, Inc.
FULC · NASDAQ
$3.84 +1.05% (+$0.04)
1M +0.00%
Market Cap $293.0M
P/E Ratio -
Div. Yield -
ROE 28.54%
Bulios Fair Price
$4.16
8.3% upside
Current Price
$3.84
Undervalued Fair Value Overvalued
According to Bulios Fair Price, FULC is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.94x
P/E N/A
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 20.61%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 27.40%
Asset turnover 0.00x
ROE 28.54%
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 31.35x
Int. coverage N/A
Stability
1 /100
Unstable Beta 3.00x
Profitable years 0
Rev. volatility 1,634.01%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about FULC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Alexander C. Sapir
Employees
9
Headquarters
Cambridge
Upcoming events
29 OCT
Earnings
Upcoming earnings report